Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria
EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria
EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria
EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria
EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria
EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment
EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
Now Viewing
EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
EP: 13.Patient Education, Provider Education, and Overall Final Thoughts
Video content above is prompted by the following question:
- Dupilumab has been evaluated in phase 3 clinical trials in patients with chronic spontaneous urticaria (CSU). What did the data show and what was the FDA’s response to the requested approval?
- There is a Bruton tyrosine kinase (BTK) inhibitor under investigation in CSU. How does the BTK pathway differ from others that are targeted by CSU therapies?
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
Related Videos
Related Content
Knowledge Gaps Persist in Patient Understanding of Skin Cancer–Related Terms
January 13th 2026Article
On average, patients with multiple prior dermatology visits still scored below 75% when identifying common skin cancer terms, underscoring the need for clearer patient-physician communication.
Read More
